

2025 Current Fiscal Year Report: National Cancer Institute Board of Scientific Advisors

Report Run Date: 05/16/2026 10:19:39 PM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2025

3. Committee or Subcommittee

National Cancer Institute Board of Scientific Advisors

3b. GSA Committee No.

1483

4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 10/08/2023 10/08/2025

8a. Was Terminated During Fiscal Year? 8b. Specific Termination Authority 8c. Actual Term Date

Yes 2025 Secretary Directive 04/01/2025

9. Agency Recommendation for Next Fiscal Year 10a. Legislation Req to Terminate? 10b. Legislation Pending?

Terminate No Not Applicable

11. Establishment Authority

Authorized by Law

12. Specific Establishment Authority 13. Effective Date 14. Committee Type 14c. Presidential?

42 U.S.C. 285a-2(b)(7) 11/20/1985 Continuing No

15. Description of Committee

Scientific Technical Program Advisory Board

16a. Total Number of Reports

No Reports for this Fiscal Year

17a. Open 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 1

Meetings and Dates

Purpose	Start	End
Program Advisory and/or Policy	12/02/2024	- 12/03/2024

Number of Committee Meetings Listed: 1

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$7,800.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$85,710.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$13,820.00	\$0.00
18e. Total Costs	\$107,330.00	\$0.00
19. Federal Staff Support Years (FTE)	0.40	0.00

20a. How does the Committee accomplish its purpose?

The Board was composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provided scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the

extramural research programs, and concept review of extramural program initiatives. It included the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considered meritorious and consistent with the Institute's programs. The advisory role of the Board was scientific and did not include deliberation on matters of public policy. In FY2025, the BSA presented reports on various topics related to cancer research in general as well as legislative matters. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: The Experimental Therapeutics Clinical Trials Network (ETCTN) (Re-issue RFA/Coop. Agr.), NCI Community Oncology Research Program (NCORP) (Re-issue RFA), Phase 4: U.S. and Low- and Middle-Income Countries (LMICs) HIV Associated Malignancy Research Centers (RFA/Coop. Agr.), Global Training for Research and Equity in Cancer (GlobTREC) (Re-issue RFA/Coop. Agr.), Cancer Intervention and Surveillance Modeling Network (CISNET) Reissue (U01 Clinical Trial Not Allowed (RFA/Coop. Agr.), Informatics Technology for Cancer Research (ITCR) (Re-issue RFA/Coop. Agr.).

20b. How does the Committee balance its membership?

The Board consisted of up to 35 members, including a Chair appointed by the NCI Director. Members are selected from authorities with expertise across a wide range of fields, including laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and

fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations were addressed in selecting members for appointment to the Board.

20c. How frequent and relevant are the Committee Meetings?

Meetings were typically held three times per year. During this reporting period, the committee convened once, meeting jointly with the National Cancer Advisory Board at the virtual session in

December 2024. The Board's deliberations were essential to reviewing a significant portion of the Institute's extramural program, including concept reviews of Requests for Applications (RFAs), Program Announcements with special receipt, referral, and review (PARs), and Research and Development (R&D) Requests for Proposals (RFPs) for contract initiatives.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

This Board was composed of distinguished biomedical research authorities from outside the NIH, ensuring unbiased and objective evaluations of extramural research programs. Their recommendations were invaluable, as the complexity of the research required a unique breadth and balance of expertise not otherwise available within the NIH or from other established sources.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Termination determined through a directive by HHS Secretary Robert F. Kennedy, Jr. in response to Executive Order 14217, Commencing the Reduction of the Federal Bureaucracy. Per "2025 Secretary Directive" this FACA Committee has been terminated. Reports: The committee did not produce any public reports. Max Number of Members Total: The Charter authorized up to 35 members, including the Chair. Members: Member term end dates differ from those reported in the FY2024 ACR due to the committee's termination. Eight members were on-boarded in FY2025 [Suzanne D. Conzen, Debra L. Friedman, William

C. Hahn, Wells A. Messersmith, Katherine A. Rendle, Charles M. Rudin, George J. Weiner, and Kris C. Wood]. DFO/Committee Decision Maker: These roles are held by the same individual based on the Institute's assignment of responsibilities.

Designated Federal Officer

PAULETTE S. GRAY DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI

Committee Members	Start	End	Occupation	Member Designation
ARE, CHANDRAKNATH	03/13/2022	03/31/2025	JERALD L. AND CAROLYN J. VARNER PROFESSOR IN SURGICAL ONCOLOGY AND GLOBAL HEALTH, ASSOCIATE DEAN FOR GRADUATE MEDICAL EDUCATION, UNIVESITY OF NEBRASKA MEDICAL CENTER	Special Government Employee (SGE) Member
			FOUNDER AND DIRECTOR, RUNX 1 RESEARCH PROGRAM	Special Government Employee (SGE) Member
BABICH, TIMOTHY	06/04/2023	03/31/2025	ASSOCIATE DIRECTOR OF BASIC SCIENCES, ST. JUDE COMPREHENSIVE CANCER CENTER, ENDOWED CHAIR IN BRAIN TUMOR RESEARCH, ST. JUDE CHILDREN'S RESEARCH HOSPITAL	Special Government Employee (SGE) Member
BAKER, SUZANNE	12/19/2021	03/31/2025	PROFESSOR, DEPARTMENT OF BEHAVIORAL SCIENCE, DIVISION OF CANCER PREVENTION AND POPULATION SCIENCE, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Special Government Employee (SGE) Member
BASEN-ENGQUIST, KAREN	12/05/2021	03/31/2025	PROFESSOR, DEPARTMENT OF MEDICINE, HARVARD MEDICAL SCHOOL, VICE CHAIR OF CLINICAL RESEARCH, DIVISION OF GASTROENTEROLOGY, MASSACHUSETTS GENERAL HOSPITAL	Special Government Employee (SGE) Member
CHAN, ANDREW	03/13/2022	03/31/2025		

CHAO, NELSON	12/05/2021	03/31/2025	DONALD D. AND ELIZABETH G. COOKE DISTINGUISHED, PROFESSOR, DIVISION OF CELL THERAPY, DEPARTMENT OF MEDICINE, DUKE UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
CONZEN, SUZANNE	11/03/2024	03/31/2025	PROFESSOR AND DIVISION CHIEF, DEPARTMENT OF MEDICINE, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	Special Government Employee (SGE) Member
CORONADO, GLORIA	12/05/2021	03/31/2025	MITCH GREENLICK ENDOWED DISTINGUISHED INVESTIGATOR IN HEALTH DISPARITIES RESEARCH, CENTER FOR HEALTH RESEARCH, KAISER PERMANENTE NORTHWEST PROFESSOR, DERPARTMENT OF FAMILY AND PREVENTIVE MEDICINE, COLLEGE OF MEDICINE, UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	Special Government Employee (SGE) Member Special Government Employee (SGE) Member
DOESCHER, MARK	02/26/2023	03/31/2025	CHIEF HEALTH EQUITY OFFICER, DIRECTOR, OFFICE OF HEALTH EQUITY, DIVERSITY, AND INCLUSION, THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER	Special Government Employee (SGE) Member
DOUBENI, CHYKE	11/21/2021	03/31/2025	DIRECTOR, UNIVERSITY OF NORTH CAROLINA LINEBERGER COMPREHENSIVE CANCER CENTER, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	Special Government Employee (SGE) Member
EARP, HENRY	03/13/2024	03/31/2025	DEPUTY DIRECTOR, VANDERBILT-INGRAM CANCER CENTER	Special Government Employee (SGE) Member
FRIEDMAN, DEBRA	10/20/2024	03/31/2025	ROBERT K. WERBE DISTINGUISHED PROFESSOR IN HEAD AND NECK CANCER, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Special Government Employee (SGE) Member
GRANDIS, JENNIFER	03/13/2022	03/21/2025		Special Government Employee (SGE) Member

HAHN, WILLIAM	10/20/2024	03/31/2025	WILLIAM ROSENBERG PROFESSOR OF MEDICINE, DEPARTMENT OF MEDICINE, HARVARD MEDICAL SCHOOL	Special Government Employee (SGE) Member
HATSUKAMI, DOROTHY	11/21/2021	03/31/2025	ASSOCIATE DIRECTOR OF CANCER PREVENTION AND CONTROL, MASONIC CANCER CENTER, PROFESSOR, DEPARTMENT OF PSYCHIATRY, UNIVERSITY OF MINNESOTA	Special Government Employee (SGE) Member
IDEKER, TREY	03/13/2022	03/31/2025	PROFESSOR, DEPARTMENT OF MEDICINE, UNIVERSITY OF CALIFORNIA, SAN DIEGO	Special Government Employee (SGE) Member
LE BEAU, MICHELLE	02/03/2019	03/21/2025	ARTHUR AND MARIAN EDELSTEIN PROFESSOR OF MEDICINE AND DIRECTOR, UNIVERSITY OF CHICAGO COMPREHENSIVE CANCER CENTER, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member
LOPEZ, ANA MARIA	02/26/2023	03/31/2025	PROFESSOR, MEDICAL ONCOLOGY AND INTEGRATIVE MEDICINE (ABOIM) AND NUTRITIONAL SCIENCES. DIRECTOR, INTEGRATIVE ONCOLOGY,	Special Government Employee (SGE) Member
MESSERSMITH, WELLS	10/20/2024	03/31/2025	ASSOCIATE DIRECTOR, DIVERSITY, EQUITY, AND INCLUSION, SIDNEY KIMMEL CANCER CENTER, NCI DESIGNATED, THOMAS JEFFERSON UNIVERSITY	Special Government Employee (SGE) Member
MUSTIAN, KAREN	03/13/2022	03/31/2025	PROFESSOR AND HEAD, DIVISION OF MEDICAL ONCOLOGY, DEPARTMENT OF MEDICINE, UNIVERSITY OF COLORADO SCHOOL OF MEDICINE DEAN'S DISTINGUISHED ENDOWED PROFESSOR OF ONCOLOGY AND SURGERY, DEPARTMENT OF RADIATION ONCOLOGY, JAMES P. WILMOT CANCER CENTER, UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE	Special Government Employee (SGE) Member

NEWMAN, LISA	06/04/2023	03/31/2025	PROFESSOR OF SURGERY, CHIEF DIVISION OF BREAST SURGERY, WEILL CORNELL MEDICINE	Special Government Employee (SGE) Member
OSAROGIAGBON, RAYMOND	02/26/2023	03/31/2025	ADJUNCT RESEARCH PROFESSOR, DEPARTMENT OF MEDICINE, VANDERBILT UNIVERSITY, CHIEF SCIENTIST, BAPTIST MEMORIAL HEALTH CARE CORPORATION	Special Government Employee (SGE) Member
RENDE, KATHARINE	11/03/2024	03/31/2025	ASSISTANT PROFESSOR, DEPARTMENT OF FAMILY MEDICINE AND COMMUNITY HEALTH, UNIVERSITY OF PENNSYLVANIA	Special Government Employee (SGE) Member
ROBERTSON, ERLE	12/05/2021	03/31/2025	HARRY P. SCHENK ENDOWED CHAIR PROFESSOR, VICE-CHAIR, DEPARTMENT OF OTORHINOLARYNGOLOGY, UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
RUDIN, CHARLES	10/20/2024	03/31/2025	DEPUTY DIRECTOR, MEMORIAL SLOAN KETTERING CANCER CENTER	Special Government Employee (SGE) Member
ULRICH, CORNELIA	02/26/2023	03/31/2025	CHIEF SCIENTIFIC OFFICER AND EXECUTIVE DIRECTOR, COMPREHENSIVE CANCER CENTER, HUNTSMAN CANCER INSTITUTE, UNIVERSITY OF UTAH	Special Government Employee (SGE) Member
VOLCHENBOUM, SAMUEL	02/12/2023	03/31/2025	ASSOCIATE PROFESSOR OF PEDIATRICS, DIRECTOR, PEDIATRIC CANCER DATA COMMONS. PRITZKER SCHOOL OF MEDICINE, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member
WEINER, GEORGE	11/03/2024	03/31/2025	C.E. BLOCK CHAIR OF CANCER RESEARCH AND PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF IOWA	Special Government Employee (SGE) Member
WOOD, KRIS	11/03/2024	03/31/2025	ASSOCIATE PROFESSOR, DEPARTMENT OF PHARMACOLOGY AND CANCER, BIOLOGY DUKE UNIVERSITY	Special Government Employee (SGE) Member

ZELLARS,
RICHARD

03/13/2022 03/31/2025

WILLIAM A. MITCHELL
PROFESSOR AND CHAIR, Special
DEPARTMENT OF Government
RADIATION ONCOLOGY, Employee
SIMON COMPREHENSIVE (SGE)
CANCER CENTER, INDIANA Member
UNIVERSITY

Number of Committee Members Listed: 30

Narrative Description

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor's (BSA). The BSA was composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provided scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This included the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA was scientific and did not include deliberation on matters of public policy. The BSA represented the scientific community's voice in the extramural science the NCI supports. As such, the Board advised the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluated NCI extramural programs, and reviewed ideas for new research opportunities and solicitations to ensure that a concept was meritorious and consistent with the Institute's mission. Additionally, the BSA believed it was important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA's deliberations were an indispensable part of the review of a very large part of the Institute's extramural program.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Outcome Comments

Based on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, behavioral modifications and cures for different cancer sites. Another outcome was the annual posting of the RFA Report.

What are the cost savings associated with this committee?

	Checked if Applies
None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

Meetings were held not less than three times a year. The committee met one time during this reporting period. The Board met jointly with the National Cancer Advisory Board for the virtual December 2024. The Board's deliberations were essential to reviewing a significant portion of the Institute's extramural program, including concept reviews of Requests for Applications (RFAs), Program Announcements with special receipt, referral, and review (PARs), and Research and Development (R&D) Requests for Proposals

(RFPs) for contract initiatives.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

557

Number of Recommendations Comments

In addition to general recommendations, specific recommendations by the committee include: 1. A motion to concur on the DCTD's re-issue RFA/Coop. Agr. entitled "The Experimental Therapeutics Clinical Trials Network (ETCTN)" was approved unanimously. 2. A motion to concur on the DCP's re-issue RFA entitled "NCI Community Oncology Research Program (NCORP)" was approved unanimously. 3. A motion to approve the DCTD's new PAR entitled "Cancer Tissue-on-Chip (ToC) Technologies for Improved Preclinical Efficacy Evaluation of Therapies in Oncology" was approved with 21 ayes, 0 nays, 0 abstentions, and 7 deferrals. 4. A motion to approve the Office of the Director's (OD) new RFA/Coop. Agr. entitled "Phase 4: U.S. and Low- and Middle-Income Countries (LMICs) HIV-Associated Malignancy Research Centers" was approved unanimously. 5. A motion to concur on DCCPS' re-issue RFA/Coop. Agr. entitled "Cancer Intervention and Surveillance Modeling Network (CISNET) Re-issuance (U01 Clinical Trial Not Allowed)" was approved unanimously. 6. A motion to approve the OD's new PAR entitled "The Academic Career Excellence (ACE) Award, Including Awards to Promote Diversity" was approved unanimously. 7. A motion to concur on the OD's re-issue RFA/Coop. Agr. entitled "Informatics Technology for Cancer Research (ITCR)" was approved unanimously. 8. A motion to approve the OD's new PAR entitled "Cancer Moonshot Scholars Program" was approved unanimously.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

90%

% of Recommendations Fully Implemented Comments

The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes No Not Applicable

Agency Feedback Comments

The NCI Director's Report was presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report was presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items was assigned to individual NCI staff with specific time frames with deadlines. Information was provided to the public at each meeting.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

Priorities were reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources were allocated based on approved concepts.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the BSA was available on the NCI Division of Extramural Activities website (<http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>), which included each committee's charter, minutes, agenda, roster, future meeting dates, presentations, and reports. BSA meetings were also accessible to the public, live and on demand, via the NIH Videocast (<http://videocast.nih.gov/>).